Esperion: Funding, Investors & Team (Sep 2026)
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
Esperion has raised $225M across 2 funding rounds on record, the most recent an undisclosed round announced in May 2026.
Esperion Company Profile and Key Stats
Latest funding round on record: May 2026.
Esperion Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Esperion raised $225M in a Post-IPO Equity announced in Dec 2021.
4.4 years later, an undisclosed round was announced in May 2026 with no disclosed amount.
Esperion Founders and Leadership Team
Contact details for the Esperion team: 1 has a LinkedIn profile.
Start 14-day free trial →Esperion Funding Compared to Other Biotechnology Startups
Funded Startups Like Esperion in Biotechnology and Ann Arbor
Companies Similar to Esperion
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Esperion Funding FAQs
What does Esperion do?
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
How much funding has Esperion raised?
Esperion has raised $225M across 2 rounds on record.
When did Esperion last raise funding?
Esperion's most recent funding round on record was announced in May 2026. The amount was not disclosed.
Who founded Esperion?
FundedIQ lists Sheldon Koenig (Founder) at Esperion.
Who is the CEO of Esperion?
Tim Mayleben is listed as CEO at Esperion.
Where is Esperion headquartered?
Esperion is based in Ann Arbor, Michigan, United States.
How many employees does Esperion have?
Esperion is in the 251-500 employee band.
About FundedIQ's Esperion Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Esperion is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.